{"drugs":["Bicalutamide","Casodex"],"mono":{"0":{"id":"923404-s-0","title":"Generic Names","mono":"Bicalutamide"},"1":{"id":"923404-s-1","title":"Dosing and Indications","sub":[{"id":"923404-s-1-4","title":"Adult Dosing","mono":"<ul><li>prior to initiating bicalutamide treatment, measure serum transaminase levels and repeat testing at regular intervals for the first 4 months, and then periodically thereafter; if ALT is greater than 2 times ULN at any time, or if the patient develops jaundice, bicalutamide should be immediately discontinued<\/li><li><b>Metastatic prostate cancer, Stage D2, in combination with a luteinizing hormone-releasing hormone (LHRH) analog:<\/b> 50 mg ORALLY once daily in conjunction with a luteinizing hormone-releasing hormone (LHRH) analog<\/li><\/ul>"},{"id":"923404-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"923404-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> dosage adjustment not necessary<\/li><li><b>hepatic impairment, mild-to-severe:<\/b> dosage adjustment not needed; if ALT is greater than 2 times ULN at any time, or if jaundice develops, discontinue immediately<\/li><li><b>hepatotoxicity during treatment:<\/b> if ALT is greater than 2 times ULN at any time, or if jaundice develops, discontinue immediately<\/li><li><b>hemodialysis:<\/b> dosage adjustment is not necessary<\/li><\/ul>"},{"id":"923404-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Metastatic prostate cancer, Stage D2, in combination with a luteinizing hormone-releasing hormone (LHRH) analog<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Hirsutism<br\/>"}]},"3":{"id":"923404-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923404-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to bicalutamide or to any component of the product<\/li><li>women; use not indicated in women, including women who are or may become pregnant; may cause fetal harm<\/li><\/ul>"},{"id":"923404-s-3-10","title":"Precautions","mono":"<ul><li>hepatotoxicity (eg, hepatitis, hepatic failure), including rare cases of hospitalization or death, has been reported; monitoring recommended; drug discontinuation may be necessary<\/li><li>hypersensitivity reactions, including angioedema and urticaria, have been reported<\/li><li>reduced glucose tolerance may occur; patients may present with diabetes or patients with preexisting diabetes may lose glycemic control; monitoring recommended<\/li><li>report suspected adverse reactions to AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"923404-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"923404-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"923404-s-4","title":"Drug Interactions","sub":{"1":{"id":"923404-s-4-14","title":"Major","mono":"<ul><li>Acenocoumarol (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Dicumarol (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><\/ul>"}}},"5":{"id":"923404-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (13%)<\/li><li><b>Dermatologic:<\/b>Hot sweats (53%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (11%), Constipation (22%), Diarrhea (12%), Nausea (15%)<\/li><li><b>Immunologic:<\/b>Infectious disease (18%)<\/li><li><b>Musculoskeletal:<\/b>Backache (25%), Pain in pelvis (21%)<\/li><li><b>Neurologic:<\/b>Asthenia (22%)<\/li><li><b>Renal:<\/b>Hematuria (12%), Nocturia (12%)<\/li><li><b>Respiratory:<\/b>Dyspnea (13%)<\/li><li><b>Other:<\/b>Pain (35%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure (2% up to 5%), Myocardial infarction (2% to less than 5%)<\/li><li><b>Hepatic:<\/b>Hepatitis, Hepatotoxicity, Liver failure<\/li><\/ul>"},"6":{"id":"923404-s-6","title":"Drug Name Info","sub":{"0":{"id":"923404-s-6-17","title":"US Trade Names","mono":"Casodex<br\/>"},"2":{"id":"923404-s-6-19","title":"Class","mono":"Antiandrogen<br\/>"},"3":{"id":"923404-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923404-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"923404-s-7","title":"Mechanism Of Action","mono":"Bicalutamide, a non-steroidal antiandrogen, competitively binds to cytosol androgen receptors in the target tissue to inhibit the action of androgens.<br\/>"},"8":{"id":"923404-s-8","title":"Pharmacokinetics","sub":[{"id":"923404-s-8-23","title":"Absorption","mono":"<ul><li>Oral: well-absorbed<\/li><li>Bioavailability: unknown<\/li><li>Effect of food: none<\/li><\/ul>"},{"id":"923404-s-8-24","title":"Distribution","mono":"Protein binding: 96% <br\/>"},{"id":"923404-s-8-25","title":"Metabolism","mono":"glucuronidation, and oxidation <br\/>"},{"id":"923404-s-8-26","title":"Excretion","mono":"<ul><li>Fecal<\/li><li>Renal<\/li><\/ul>"}]},"9":{"id":"923404-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>administer with or without food, at the same time each day <br\/>"},"10":{"id":"923404-s-10","title":"Monitoring","mono":"<ul><li>serum PSA; periodically or as indicated to assess therapeutic response<\/li><li>evidence of prostate tumor response is indicative of efficacy<\/li><li>blood glucose; in patients receiving combination therapy with a luteinizing hormone-releasing hormone agonist<\/li><li>liver function tests, periodically; in hepatically-impaired patients on long-term therapy<\/li><li>serum transaminases; baseline, at regular intervals for the first 4 months of therapy, and periodically thereafter<\/li><li>serum ALT at first sign or symptom suggestive of liver-dysfunction (nausea\/vomiting, abdominal pain, and dark urine)<\/li><\/ul>"},"11":{"id":"923404-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 50 MG<br\/><\/li><li><b>Casodex<\/b><br\/>Oral Tablet: 50 MG<br\/><\/li><\/ul>"},"12":{"id":"923404-s-12","title":"Toxicology","sub":[{"id":"923404-s-12-31","title":"Clinical Effects","mono":"<b>BICALUTAMIDE<\/b><br\/>OVERDOSE: No human data.  ADVERSE EFFECTS: hot flashes (49%), general pain (27%), constipation (17%), asthenia (15%) and hypertension (5%) seen with advanced prostate cancer treated patients taking bicalutamide & a LHRH analogue. Effects reported with monotherapy: dizziness, confusion, nausea (3-8%), vomiting (4-7%), rash (6%), and hepatitis (&lt;2%). <br\/>"},{"id":"923404-s-12-32","title":"Treatment","mono":"<b>BICALUTAMIDE <\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: Therapy as indicated<\/li><li>Monitoring of patient: Vitals signs; fluid and electrolyte status with significant GI loss.  Monitor CNS function.<\/li><\/ul>"},{"id":"923404-s-12-33","title":"Range of Toxicity","mono":"<b>BICALUTAMIDE<\/b><br\/>Doses up to 200 mg\/day have been well tolerated. A toxic dose has NOT been established. <br\/>"}]},"13":{"id":"923404-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient that drug may cause infertility, at least temporarily. Family planning should be discussed with healthcare provider prior to therapy with drug.<\/li><li>This drug may cause gynecomastia, hot flashes, diarrhea, nausea, asthenia, or hepatotoxicity.<\/li><li>Advise patient to report signs\/symptoms of gastrointestinal or rectal hemorrhage, or anemia.<\/li><li>Instruct patient to report symptoms of liver dysfunction, especially hepatic-impaired patients on long-term therapy.<\/li><li>Patient should take drug at the same time each day.<\/li><\/ul>"}}}